#United States #NASDAQ #Biopharmaceutical #Bridgewater #Insmed

Insmed Inc. Announces Employee Inducement Grants

Bridgewater, N.J. — September 4, 2026
Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company dedicated to delivering groundbreaking therapies, has made headlines with its recent decision to grant inducement awards to 128 new employees. This initiative aligns with its commitment to attract and retain top talent while adhering to NASDAQ's compliance requirements stipulated in Listing Rule 5635(c)(4).

The awards are part of the Insmed Incorporated 2025 Inducement Plan, designed specifically for this purpose. Approved by the company's Compensation Committee, these awards serve as a significant motivator for new hires, reflecting Insmed’s commitment to building a dynamic workforce. On August 31, 2026, the new employees received a total of 115,320 restricted stock units (RSUs) and options for purchasing 5,560 shares of Insmed common stock, all at an exercise price of $121.82 per share—this figure corresponding to the market's closing price on the grant day.

A Closer Look at the Inducement Plan

The RSUs come with a vesting schedule spread across four years. Each year, 25% of the shares associated with the RSUs will vest, contingent upon the employee’s continued employment with Insmed. This structured vesting process not only encourages employee retention but also aligns the interests of the employees with those of the company.

Similarly, the stock options are offered for a term of ten years, featuring a vesting schedule that mirrors that of the RSUs. The initial 25% of the shares will vest after the first anniversary of the grant date, with subsequent vesting of 12.5% every six months, reinforcing long-term commitment and performance incentives.

Insmed's Vision and Commitment

Founded with a people-first philosophy, Insmed aims to transform the lives of patients suffering from severe diseases through innovative therapies. Their offerings center around a versatile portfolio that includes both approved treatments for chronic lung diseases and a broad spectrum of investigational medicines. The organization places a strong emphasis on using cutting-edge research techniques, encompassing technologies such as gene therapy and AI-driven drug discovery, to address real patient needs.

Insmed's operations span multiple regions, including the U.S., Europe, and Japan, thereby enhancing its capabilities to serve diverse patient communities. Recognized for its exemplary workforce culture, the company has consistently been rated among the top employers in the biopharmaceutical sector for five consecutive years, highlighting its dedication to employee well-being and professional development.

As the biopharmaceutical landscape continues to evolve, Insmed remains steadfast in its mission to deliver first- and best-in-class solutions, aiming for a future where serious diseases can be effectively managed and ultimately cured. The recent inducement awards illustrate the company’s strategic approach toward cultivating an engaged and high-performing workforce, essential for driving innovation forward.

For more information, visit Insmed's official website or follow their updates on LinkedIn, Instagram, YouTube, and Twitter for future announcements and insights into their ongoing research and developments.

Conclusion

In summary, Insmed's latest inducement grants are a clear indication of the company's commitment to both its employees and its overarching mission of changing lives through revolutionary therapies. By integrating compliance with talent acquisition strategies, Insmed is not only enhancing its workforce but also solidifying its position as a leader in the biopharmaceutical industry.